Orexo regains rights to Zubsolv® in all countries outside the US
(WorldNews Sweden)

Uppsala, Sweden - December 13, 2018 - Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will regain the rights to Zubsolv (buprenorphine and naloxone sublingual tablet) for the treatment of opioid dependence in all territories outside the United States from its current partner, Mundipharma, on April 13, 2019. Mundipharma has seen Zubsolv successfully approved in Europe through a centralized procedure and has launched the product in selected markets such as Germany and Sweden. Following a portfolio reorganization, they have...